Treatment of prostatic carcinoma with polyestradiol phosphate combined with ethinylestradiol.
D000328:Adult; D000367:Age Factors; D000368:Aged; D000728:Androgens / Q000378:metabolism; D002277:Carcinoma / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy* / Q000401:mortality; D002318:Cardiovascular Diseases / Q000150:complications* / Q000401:mortality; D004967:Estrogens / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004997:Ethinyl Estradiol / Q000008:administration & dosage / Q000627:therapeutic use*; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D011471:Prostatic Neoplasms / Q000150:complications / Q000188:drug therapy* / Q000401:mortality; D013737:Testis / Q000378:metabolism; D014547:Urinary Diversion; D014555:Urination Disorders / Q000150:complications
D000728:Androgens; D004967:Estrogens; D004997:Ethinyl Estradiol